Mirza Mansoor Raza, a director at Sera Prognostics , Inc. (NASDAQ:SERA), recently sold a portion of his holdings in the company. The transaction comes as the stock trades near its 52-week low of $2.10, having declined over 77% in the past year. According to InvestingPro analysis, the company currently shows signs of being slightly undervalued. According to a recent SEC filing, Raza sold 106 shares of Class A Common Stock on May 8, 2025, at a weighted average price of $2.44 per share, totaling approximately $258. This transaction was executed to cover tax withholding obligations related to the vesting of restricted stock units. Following the sale, Raza holds 43,672 shares directly in the $83 million market cap company. InvestingPro subscribers can access additional insights, including 13 more ProTips and comprehensive insider trading analysis in the Pro Research Report.
In other recent news, Sera Prognostics reported its Q1 2025 earnings, showcasing a narrower-than-expected loss with an EPS of -$0.20, surpassing analyst projections of -$0.27. However, the company’s revenue of $38,000 fell short of the anticipated $200,000, marking a start from zero revenue in the same quarter last year. Despite the revenue miss, the company continues to focus on commercialization and market expansion, particularly targeting Medicaid and specific geographic regions. In a strategic move, Sera Prognostics has appointed Lee Anderson as its new Chief Commercial Officer, a decision expected to bolster the commercial expansion of its products. Anderson’s extensive experience in healthcare leadership is anticipated to enhance sales strategies and foster innovation. The company is also progressing with its Medicaid pilot programs and preparing for potential updates in clinical guidelines by 2026-2028. Analysts from William Blair and TD Cowen have shown interest in the company’s strategic direction and potential for future growth, reflecting investor optimism despite current revenue challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.